Back to Journals » Therapeutics and Clinical Risk Management » Biologic Treatment for Allergic Disease
SJR OA
CiteScore
Impact Factor
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2599)
- Volume 22, 2026 (43)
- Volume 21, 2025 (162)
- Volume 20, 2024 (86)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Journal Articles:
- Older and newer players in the therapeutics of Cardio-Kidney-Metabolic syndrome (1)
- Machine Learning in the Realm of Therapeutics and Clinical Risk Management (1)
- Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications (1)
- Anticholinergic Therapies for the Treatment of Asthma (7)
Biologic Treatment for Allergic Disease
Since their clinical introduction, biologic treatments, particularly monoclonal antibodies, have transformed patient care, offering targeted therapies and improved outcomes for conditions including allergic asthma, allergic rhinitis, atopic dermatitis and urticaria. Given the importance of biologics in managing allergic disease, we here collect original research articles, reviews, and perspectives exploring the mechanisms of action, clinical efficacy, safety, and real-world application of these therapies.
